Fulgent Genetics
Tracked across 2 events · 14 articles · First seen May 21, 2026 · Last active Jul 09, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Fulgent Genetics announced positive interim results from its Phase 2 study of FID-007, which could significantly advance its therapeutic development business and potentially lead to a Phase 3 study. This positive data could increase investor confidence and its stock price.
May 21, 2026 · 8 articles
Business
Impact: Fulgent Genetics is the subject of the event, announcing its Q2 2026 earnings release date.
Jul 09, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Fulgent Genetics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard